Quick Answer
INTEGRATED BIOPHARMA INC reported Long Term Debt of $7.0 thousand for the year ending 2023.
- INTEGRATED BIOPHARMA INC showed a decrease of -86.8% in Long Term Debt from 2022 to 2023.
- This data is from INTEGRATED BIOPHARMA INC's annual report (Form 10-K), filed with the SEC on September 15, 2023.
- XBRL data for this metric is available from 2012 to 2023 (12 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q3 2012: $4.56 million | Q4 2012: $5.09 million | Q1 2013: $4.99 million | Q3 2013: $4.74 million | Q4 2013: $4.36 million | Q1 2014: $4.50 million | Q3 2014: $4.42 million | Q4 2014: $4.30 million | Q1 2015: $4.08 million | Q2 2015: $3.94 million | Q3 2015: $3.83 million | Q4 2015: $3.79 million | Q1 2016: $5.55 million | Q3 2016: $4.87 million | Q4 2016: $4.71 million | Q1 2017: $4.61 million | Q3 2017: $3.77 million | Q4 2017: $3.88 million | Q1 2018: $3.73 million | Q3 2018: $3.32 million | Q4 2018: $3.08 million | Q3 2019: $2.18 million | Q4 2019: $1.90 million | Q1 2020: $1.65 million | Q3 2020: $654.0 thousand | Q4 2020: $470.0 thousand | Q1 2021: $40.0 thousand | Q3 2022: $39.0 thousand | Q4 2022: $28.0 thousand | Q1 2023: $18.0 thousand | Q2 2023: $7.0 thousand | Q1 2024: $0.00.
- Over the full 12 years of available data (2012 to 2023), INTEGRATED BIOPHARMA INC's Long Term Debt has declined by 99.9%.
- Historical annual values: Fiscal year 2023: $7.0 thousand | Fiscal year 2022: $53.0 thousand | Fiscal year 2021: $0.00 | Fiscal year 2020: $1.44 million | Fiscal year 2019: $2.72 million | Fiscal year 2018: $3.62 million | Fiscal year 2017: $4.25 million | Fiscal year 2016: $5.24 million | Fiscal year 2015: $3.94 million | Fiscal year 2014: $4.36 million | Fiscal year 2013: $4.89 million | Fiscal year 2012: $4.70 million.
- Data sourced from SEC EDGAR public filings as of August 6, 2026.
Last verified: